Physician profile
James Throneberry
NPI 1316949308
$9,750.55
in general payments reported to CMS, 2019-2025
52 companies · $1,630 in 2025
The $1,630 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,577 · 2020: $883 · 2021: $1,464 · 2022: $1,269 · 2023: $1,394 · 2024: $1,533 · 2025: $1,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,508 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,507.55 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,806.24 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,013.21 | 2019-2025 | |
| Lilly USA, LLC | $853.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $714.48 | 2021-2025 | Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $536.14 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $492.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $486.28 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $341.46 | 2019-2022 | |
| Amgen INC. | $286.83 | 2019-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $256.07 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.28 | 2019-2023 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $239.36 | 2020-2021 | |
| Amarin Pharma, INC. | $207.49 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.99 | 2019-2024 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $169.24 | 2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Throneberry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.